Loading...

FOLD AMICUS THERAPEUTICS INC Company Mergers 8-K Filing

MCS

FLD

AMICUS THERAPEUTICS INC

(FOLD)

2025 8-K

Merger Approved

Financial Results Announced

Acquisition Update

Merger Announcement

Financial Results Update

Financial Statements

Financial Statements

Asset Acquisitions

Earnings Report

Earnings Update

Earnings Update

Earnings Update

Quantitative Data

Quantitative Data

Quantitative Data

Financial Performance Data

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Other Special Situation

Quantitative Data

Quantitative Data

Filing with Quantitative Data

Quantitative Data

Filing with Quantitative Data

Financial Performance Data

External Links:

On April 28, 2025, Amicus Therapeutics entered into a $30 million License Agreement with Dimerix for exclusive rights to develop and commercialize the drug DMX-200 for Focal Segmental Glomerulosclerosis, along with potential milestone payments of up to $590 million. Additionally, Amicus amended its loan agreement to incorporate the new licensing deal.

AI Assistant

AMICUS THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.